At the 2013 Cardiovascular Research Technologies (CRT) meeting, technological innovation for aortic valve disease assumed the spotlight. Presenters highlighted new developments in optimal delivery design for percutaneous valves.
Though Edwards Lifesciences’ Sapien Valve remains the only commercially approved transcatheter aortic valve replacement (TAVR) device in the U.S., 10 new devices are in the pipeline. Medtronic’s CoreValve is second closest to market. Whereas past CRT discussions have centered on TAVR’s safety and efficacy, debates this year focused on delivery mechanism, namely balloon- versus self-expandable devices.
Optimizing TAVR design: Balloon vs. self-expandable devices
Structural heart disease—the strongest CV growth opportunity for the next five years—took center stage at last week’s Cardiovascular Research Technologies (CRT) conference in Washington, D.C. Unexpectedly, program structure and strategy took precedence over technology innovation in presentations and discussions.
Time and again, physicians and program leaders from all over the country reinforced a message that has become a common refrain in structural heart disease treatment and cardiovascular services more broadly: multidisciplinary collaboration is essential for success.
The biggest opportunity in structural heart treatment isn't clinical
With 2013 in full swing, we’ve taken a step back to review the major CV technology stories of 2012. From devices gaining FDA approval to therapies demonstrating paradigm-shifting potential, 2012 was a year of significant innovation across CV services. To help CV leaders nationwide distill the most impactful new research, data, and FDA approvals, we’ve broken down the four top stories of 2012 and what you need to know in 2013.
Top cardiovascular technology trends of 2012